Evogene Ltd. (EVGN) vs Pulmatrix, Inc. (PULM)

Evogene Ltd. and Pulmatrix, Inc. are both Biotechnology companies. Evogene Ltd. and Pulmatrix, Inc. are of similar size ($6.3M and $6.1M). Pulmatrix, Inc. grew revenue faster over the last twelve months: 6.96% against −54.7%. Pulmatrix, Inc. has the higher net margin (0.00% vs −547.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Pulmatrix, Inc. leads on 10 and Evogene Ltd. on 6.

Valuation

Metric EVGN PULM Biotechnology median
P/E n/m n/m 7.88
P/S 3.09 0.76 11.47
P/B 0.89 3.74 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.39 n/m 0.74
EV/Sales (2.55) 1.50 10.73
Earnings yield (216.67%) (67.48%) (28.84%)
Free cash flow yield (210.40%) (72.37%) (23.03%)

Profitability

Metric EVGN PULM Biotechnology median
Gross margin (67.59%) 100.00% 65.16%
Operating margin (851.42%) 0.00% 0.00%
Net margin (547.62%) 0.00% 0.00%
Free cash flow margin (650.63%) 0.00% 0.00%
Return on equity (100.03%) (111.99%) (57.72%)
Return on assets (38.31%) (85.74%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric EVGN PULM Biotechnology median
Revenue growth (TTM) (54.71%) 6.96% 5.64%
EPS growth (last fiscal year) 62.63% 46.18% —
Revenue growth, 5-year CAGR 29.94% (0.26%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric EVGN PULM Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.57 4.70 4.73
Net debt to EBITDA 1.12 0.79 0.96

Dividend

Metric EVGN PULM Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric EVGN PULM Biotechnology median
Market cap 6.32m 6.10m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack